Fludarabine
Squamous Cell Lung Cancer
Intima Bioscience, Inc.Small moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
46 Active assets in the Squamous Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Qilu Hospital of Shandong University | Phase 4 | BBB |
Carboplatin zhang yi | Phase 3 | BBB |
Docetaxel Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Cyclophosphamide UNC Lineberger Comprehensive Cancer Center | Phase 3 | BB |
ETOPOSIDE Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →